Alkermes’ Corporate Presentation to be Webcast at the 14th Annual BIO CEO & Investor Conference

DUBLIN--(BUSINESS WIRE)-- Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the 14th Annual BIO CEO & Investor Conference on Monday, February 13, 2012, at 2:30 p.m. EST (7:30 p.m. GMT) from the Waldorf=Astoria Hotel in New York City. The presentation may be accessed under the Investor tab on www.alkermes.com and will be archived for 14 days.

Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to develop innovative medicines that improve patient outcomes. The company has a diversified portfolio of more than 20 commercial drug products and a substantial clinical pipeline of product candidates that address central nervous system (CNS) disorders such as addiction, schizophrenia and depression. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts and manufacturing facilities in Athlone, Ireland; Gainesville, Georgia; and Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.



CONTACT:

Alkermes plc
Eva Stroynowski, +1 781-609-6823
Corporate Communications

KEYWORDS:   United Kingdom  United States  Europe  North America  Massachusetts  New York  Ireland

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Professional Services  Finance  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.

The €875 million deal gives Sanofi global rights to therapies that could mitigate an efficacy-limiting shortcoming of anti-CD38 antibodies.

Salk scientists identified genes that control the activity of key immune cells, which could inspire ideas for treating cancer and autoimmune diseases.